Showing 1 - 6 results of 6 for search 'Kahaku Emoto', query time: 0.03s Refine Results
  1. 1
    Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan

    Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan by Hiroyuki Nagase, Mitsuru Adachi, Kazuto Matsunaga, Atsushi Yoshida, Tomoko Okoba, Nobuya Hayashi, Kahaku Emoto, Yuji Tohda

    Published 2020-01-01
    Get full text
    Article
  2. 2
    Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials

    Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials by Yoshiya Tanaka, Tatsuya Atsumi, Daniel Aletaha, Beatrix Bartok, Alena Pechonkina, Ling Han, Kahaku Emoto, Shungo Kano, Vijay Rajendran, Tsutomu Takeuchi

    Published 2022-11-01
    Get full text
    Article
  3. 3
    Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate

    Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate by Yoshiya Tanaka, Peter C. Taylor, Emon Elboudwarej, Angie Hertz, Xiaorong Shao, Vladislav A. Malkov, Hironori Matsushima, Kahaku Emoto, Bryan Downie, Tsutomu Takeuchi

    Published 2023-07-01
    Get full text
    Article
  4. 4
    Correction: Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate

    Correction: Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexat... by Yoshiya Tanaka, Peter C. Taylor, Emon Elboudwarej, Angie Hertz, Xiaorong Shao, Vladislav A. Malkov, Hironori Matsushima, Kahaku Emoto, Bryan Downie, Tsutomu Takeuchi

    Published 2023-11-01
    Get full text
    Article
  5. 5
    Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study

    Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study by Bernard G. Combe, Yoshiya Tanaka, Maya H. Buch, Peter Nash, Gerd R. Burmester, Alan J. Kivitz, Beatrix Bartok, Alena Pechonkina, Katrina Xia, Kahaku Emoto, Shungo Kano, Thijs K. Hendrikx, Robert B. M. Landewé, Daniel Aletaha

    Published 2023-01-01
    Get full text
    Article
  6. 6
    Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study

    Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study by Bernard G. Combe, Yoshiya Tanaka, Maya H. Buch, Peter Nash, Gerd R. Burmester, Alan J. Kivitz, Beatrix Bartok, Alena Pechonkina, Katrina Xia, Kahaku Emoto, Shungo Kano, Thijs K. Hendrikx, Robert B. M. Landewé, Daniel Aletaha

    Published 2022-10-01
    Get full text
    Article

Search Tools: